Phosphorylated retinoblastoma protein is a potential predictive marker of irinotecan efficacy for colorectal cancer

  • Authors:
    • Atsushi Ikai
    • Motoki Watanabe
    • Yoshihiro Sowa
    • Mitsuo Kishimoto
    • Akio Yanagisawa
    • Hitoshi Fujiwara
    • Eigo Otsuji
    • Toshiyuki Sakai
  • View Affiliations

  • Published online on: January 12, 2016     https://doi.org/10.3892/ijo.2016.3332
  • Pages: 1297-1304
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Irinotecan has been used in the first-line treatment of metastatic colorectal cancer. However, no clear predictive marker of irinotecan efficacy has been identified. It is controversial whether the response to irinotecan could be predicted by the expression level of topoisomerase-I, a direct target of irinotecan. The present study aimed to identify a feasible predictive marker of irinotecan efficacy. We hypothesized that the efficacy of SN38 (an active metabolite of irinotecan) is related to the cell proliferation and the phosphorylation status of RB in colorectal cancer cells. Indeed, the IC50 of SN38 was positively correlated with the doubling time of each cell line (R2=0.9315). Moreover, the phosphorylation level of RB was related to SN38 sensitivity. Consistent with the in vitro data, colorectal cancer tissues of irinotecan responders showed a significantly higher rate of phosphorylated RB (serine 780) expression using immunohistochemistry (P=0.0006), although a generally used proliferative marker, Ki-67, showed no significance. Finally, we investigated whether the phosphorylation of RB plays a crucial role in the efficacy of irinotecan. To suppress the expression of phosphorylated RB, we performed the knockdown of CDKs, which are known to phosphorylate RB. Intriguingly, the knockdown of both CDK4 and CDK6, but not CDK2, allowed RB to become the most hypophosphorylated form and converted the SN38-sensitive cells to a resistant state. Taking together the above findings from in vitro and clinical research, the immunohistochemistry of phosphorylated RB protein might be feasible to predict the irinotecan efficacy of colorectal cancer in clinical practice.
View Figures
View References

Related Articles

Journal Cover

March 2016
Volume 48 Issue 3

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Ikai, A., Watanabe, M., Sowa, Y., Kishimoto, M., Yanagisawa, A., Fujiwara, H. ... Sakai, T. (2016). Phosphorylated retinoblastoma protein is a potential predictive marker of irinotecan efficacy for colorectal cancer. International Journal of Oncology, 48, 1297-1304. https://doi.org/10.3892/ijo.2016.3332
MLA
Ikai, A., Watanabe, M., Sowa, Y., Kishimoto, M., Yanagisawa, A., Fujiwara, H., Otsuji, E., Sakai, T."Phosphorylated retinoblastoma protein is a potential predictive marker of irinotecan efficacy for colorectal cancer". International Journal of Oncology 48.3 (2016): 1297-1304.
Chicago
Ikai, A., Watanabe, M., Sowa, Y., Kishimoto, M., Yanagisawa, A., Fujiwara, H., Otsuji, E., Sakai, T."Phosphorylated retinoblastoma protein is a potential predictive marker of irinotecan efficacy for colorectal cancer". International Journal of Oncology 48, no. 3 (2016): 1297-1304. https://doi.org/10.3892/ijo.2016.3332